TY - JOUR
T1 - Recurrence after negative second-look laparotomy for ovarian cancer
T2 - Analysis of risk factors
AU - Rubin, Stephen C.
AU - Hoskins, William J.
AU - Hakes, Thomas B.
AU - Markman, Maurie
AU - Cain, Joanna M.
AU - Lewis, John L.
PY - 1988/11
Y1 - 1988/11
N2 - To determine the long-term rate of recurrence and define risk factors for recurrence, we have analyzed clinical information on 83 patients followed up for a minimum of 4 years (median, 69 months) after negative second-look laparotomy. Overall, 21 of 83 patients (25.3%) had a recurrence. Median interval to recurrence was 14 months. Stage, grade, and type of chemotherapy were significantly related to risk of recurrence. In patients with stage I disease only one of 27 (3.7%) had a recurrence. Patients with stage I disease were not included in further analysis of risk factors. In stages II, III, and IV, 20 of 56 patients (35.7%) had a recurrence. Recurrence rates by grade (excluding stage I) are as follows: grade 1, three of 21 (14.3%); grade 2, six of 17 (35.5%), and grade 3, 11 of 17 (64.7%). Platinum-treated patients in stages II, III, and IV had a 50% ( 12 24) recurrence rate compared with 25% in nonplatinum-treated patients ( 8 32) (p = 0.05). Differences in disease-free survival between platinum- and nonplatinum-treated patients were significant at the p = 0.02 level. When treated with platinum-based regimens, more patients will achieve complete clinical remission and subsequently negative second-look laparotomy. However, the recurrence rate in these patients is considerably higher than that in patients treated for longer durations with nonplatinum regimens.
AB - To determine the long-term rate of recurrence and define risk factors for recurrence, we have analyzed clinical information on 83 patients followed up for a minimum of 4 years (median, 69 months) after negative second-look laparotomy. Overall, 21 of 83 patients (25.3%) had a recurrence. Median interval to recurrence was 14 months. Stage, grade, and type of chemotherapy were significantly related to risk of recurrence. In patients with stage I disease only one of 27 (3.7%) had a recurrence. Patients with stage I disease were not included in further analysis of risk factors. In stages II, III, and IV, 20 of 56 patients (35.7%) had a recurrence. Recurrence rates by grade (excluding stage I) are as follows: grade 1, three of 21 (14.3%); grade 2, six of 17 (35.5%), and grade 3, 11 of 17 (64.7%). Platinum-treated patients in stages II, III, and IV had a 50% ( 12 24) recurrence rate compared with 25% in nonplatinum-treated patients ( 8 32) (p = 0.05). Differences in disease-free survival between platinum- and nonplatinum-treated patients were significant at the p = 0.02 level. When treated with platinum-based regimens, more patients will achieve complete clinical remission and subsequently negative second-look laparotomy. However, the recurrence rate in these patients is considerably higher than that in patients treated for longer durations with nonplatinum regimens.
KW - Antineoplastic Agents/therapeutic use
KW - Drug Therapy, Combination
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Laparotomy
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Neoplasm Staging
KW - Ovarian Neoplasms/drug therapy
KW - Reoperation
KW - Risk Factors
UR - http://www.scopus.com/inward/record.url?scp=0024233112&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:A1988R076700017&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/0002-9378(88)90420-6
DO - 10.1016/0002-9378(88)90420-6
M3 - Article
C2 - 3189442
SN - 0002-9378
VL - 159
SP - 1094
EP - 1098
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 5
ER -